Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

Stopped early · Phase 2

Conditions studied: Renal Transplant

In brief

Belatacept is an experimental medication shown in clinical trials to have immune system suppression properties in people who have had renal (e.g., kidney) transplants. This study will determine whether a combination of anti-rejection drugs, including belatacept, can prevent the rejection of a first-time, non-human leukocyte antigen (HLA) identical renal transplant and allow patients to be safely withdrawn from anti-rejection therapy one year post-transplant.

Key facts

Study ID

NCT00346151

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

5

Starts

2006-12-01

Expected to finish

2010-02-01

Last updated by the study team

2017-04-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Receiving first renal (e.g., kidney) transplant
• Transplant is from a non-HLA-identical living donor
• Willing to use acceptable forms of contraception

You may not qualify if…

• Positive for anti-human globulin (AHG) or T-cell cross-match with the donor
• Receiving multiple-organ transplant
• History of cancer within the 5 years prior to study entry. Patients who have certain nonmelanoma skin cancers are not excluded
• Human immunodeficiency virus (HIV) infected
• Hepatitis B (HBV) or C (HCV) virus infected
• Other active infections
• Active tuberculosis (TB) infection within the 3 years prior to study entry
• Pregnancy or breastfeeding

Where it is running

• University of California, San Francisco — San Francisco, California, United States
• Emory University — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.